Placeholder Banner

BIO Convention 2012: Biotech IP and Tech Transfer Sessions

April 17, 2012
Recent court decisions and ongoing implementation of the America Invents Act are certain to impact the life sciences industry. The 2012 BIO International Convention will feature an educational track devoted to Biotech Patenting and Tech Transfer to discuss legal and legislative developments and how they are likely to impact biotech companies.   This year’s global event for biotechnology will take place June 18-21, 2012 at the Boston Convention and Exhibition Center in Boston, MA.

Recent Developments in Patentability: Prometheus, Myriad, Classen, and the Patentability of Diagnostic Methods

Gain insights on major court cases—and the decision-making behind them—from a distinguished panel of patent law experts, attorneys and practitioners.

American Invents Act Comes to Campus: the Impact on Commercialization and Technology Transfer Offices

Panelists will discuss how the AIA affects universities and non-profit research institutions and what new strategies they can use to secure and enforce U.S. patents.  Learn pragmatic approaches to satisfy the AIA’s new requirements for patent procurement while improving your goals of timely technological disclosures.

IP Issues Affecting Biomarker Diagnostics and Personalized Medicine

A lively panel of international attorneys will get you up to speed on the impact that recent court cases, legislation and scientific issues—specific to inventions in the field of biomarkers and PM—have on patent procurement and protection. Have your questions ready for the audience Q&A!

Prior User Rights and Trade Secrets: A New IP Option Replacing Patents to Secure Freedom-to-Operate for Internally-Used Innovations in Biotechnology

Deciding whether it’s worth the trouble to patent internally-used technology? We will help you consider whether Prior User Rights, which serve as a defense against infringement of a later patent, might be a better option in your situation.

Academic Medical Centers: The New Pharma R&D Engine and Beyond

Developing 10% of all FDA-approved drug applications, AMCs are indispensible to life sciences. But academia-pharma partnerships are challenging. Looking at case studies of successful collaborations, we’ll uncover new pharma/biotech R&D strategies for partnering directly with AMCs to develop IP.

Challenges and Opportunities of Protecting and Managing IP Assets in Emerging Markets

How can you better protect your IP assets in emerging markets such as Brazil, Russia, India and China—or will enforce IP at all? Gain a handle on the issues involved to determine what you want—and need—to do.

Measuring The Impacts of Innovation: What Is The Future of Tech Transfer?

Tech transfer metrics that focus on activity—rather than impact—are a case of the tail wagging the dog. Join a vibrant roundtable discussion on initiatives to create more meaningful metrics, ones that will be useful in developing strategies for future transfers.

Successful IP Strategies for Biotech Platform Technologies

Many standard IP strategies are a poor fit for companies like yours. We’ll share real-world strategies that are better tailored to your needs and can evolve with your company as it grows more product-driven.

Patenting Under the America Invents Act in Comparison with European Patent Practice

Get the inside scoop—and gain international perspective—as representatives from the European Patent Office and U.S. Patent and Trademark Office discuss First to File, Prior Art and Opposition Proceedings in the two systems.

The New World: Post-Grant Review In the United States--What Can We Learn From Past Experiences In Europe, Japan, India and Australia

Hot Topic! Explore the important changes AIA has brought to U.S. patent laws. In this interactive session, a panel of international experts will take you through other countries’ histories and the growing pains they experienced in developing their post-grant review systems.

IP Challenges to Personalized Medicine & Diagnostics (Personalized Medicine and Diagnostics Track)

Hot Topic! How might recent court decisions (e.g., Myriad, Classen, and Prometheus) and emotionally charged public perception affect the obtainability of personalized medicine patents? More broadly, what are the ramifications for other technologies—perhaps those of your company—if such inventions are deemed ineligible for patents?